



Samuel Hochstrasser

Senior Associate, M.A. HSG in Law and Economics, Attorney-at-law, LL.M.

samuel.hochstrasser@nkf.ch
D +41 58 800 84 43

Languages

German, English, French

Expertise

Samuel Hochstrasser is a member of the Transactions Team of Niederer Kraft Frey. His practice focuses on private and public M&A, capital markets and private equity transactions. Additionally, his expertise includes corporate, commercial and contract law. He has particular knowledge of the life sciences sector, advising on regulatory and legal in life science matters.

Corporate / M&A

Commercial

Capital Markets

Private Equity

Career

- 2022 Senior Associate, Niederer Kraft Frey
- 2017 Associate, Niederer Kraft Frey
- 2015 Clerk with the District Court of Aarau
- 2014 Junior Associate, Niederer Kraft Frey

Education

- 2020 LL.M., Keio University, Tokyo, Gerald P. McAlinn Price in International and Comparative Law
- 2016 Admitted to the Bar (Rechtsanwalt)
- 2014 University of St. Gallen, Master of Arts HSG in Law and Economics
- 2012 University of Texas, School of Law, Exchange Semester
- 2011 University of St. Gallen, Bachelor of Arts HSG in Law and Economics

Experience

Matters in which Samuel acted as counsel include the representation of:

- Affidea in connection with the acquisition of Die Berner Urologen AG to expand its urology network (2026)
- Medermis clinics in connection with the acquisition of Dermazentrum Schaffhausen AG (2026)
- Catexel in connection with BASF's optical brightening business (2025)
- EssilorLuxottica in connection with the acquisition of RetinAI, accelerating transformative AI and data-powered eye health solutions (2025)
- Softbank in connection with the acquisition of ABB's robotic business (2025)
- Medermis clinics entering into a partnership with Mediplaza AG operating the PLAZA Kliniken (2025)
- Storskogen in connection with its acquisition of LEP AG, a leading digital healthcare documentation provider (2025)
- Affidea in connection with the investment in b-rayZ, amedical technology company focusing on AI breast imaging (2025)
- Medermis clinics in connection with the partnership with Zentrum für Gefässmedizin Mittelland AG (Aarau and Baden), Gefässpraxis am See AG (Lucerne and Cham) and Venenzentrum Arlesheim AG (Arlesheim) (2025)
- Affidea in connection with the acquisition of Uroviva Group (2025)
- Qatar Investment Authority in connection with the investment in Audi's F1 project (2024)
- Moving Spine in its financing round (2024)
- Smart Building & Industrial Services GmbH in connection with its acquisition of Swibox Holding AG (2024)
- Swiss Steel in the divestiture of its Eastern European entities (2023)
- Macquarie Asset Management in its USD 325m investment in Atlas Agro Holding AG (2023)
- SIX listed Autoneum in its rights offering (2023)
- Affidea in connection with its acquisitions of Brust-Zentrum Zurich and Plastic Surgery Group (2022/2023)
- Marché Restaurants in connection with its acquisition of Popeyes Restaurants (2022)
- NYSE and Mexican Stock Exchange listed FEMSA in the CHF 1.14 billion public takeover of SIX listed Valora Holding (2022)
- SVB Securities, Piper Sandler and LifeSci Capital as joint bookrunners/financial advisors in the public offering and private placement of Nasdaq listed VectivBio Holding AG (2022)
- International Chemical Investors Group (ICIG) on the sale of CordenPharma to European private equity firm Astorg (2022)
- SIX listed SFS Group on the acquisition of Hoffmann SE (2021)
- Coop in connection with the acquisition of Interkauf AG (operating the shopping center Perry Center, Oftringen) (2021)
- Transgourmet in connection with the acquisition of GM Food, Spain operating cash & carry markets (2021)
- Polypeptide Group AG in its CHF 848 million initial public offering and listing on SIX (2021)
- Coop on the acquisition of Jumbo from Maus Frères SA (2021)

- Swiss Steel in connection with the contested CHF 247m capital increase (2021)
- NEC Corporation in the CHF 2.05bn acquisition of Swiss Avaloq Group (2020)
- ASSA ABLOY on the acquisition of a controlling stake in agta record ag (2019)
- Worldline (Atos) in the CHF 2.75 billion acquisition of SIX Payment Services (2018)
- Landis+Gyr Group and its shareholders Toshiba and INCJ in the dual track exit process resulting in the CHF 2.3 billion IPO of Landis+Gyr Group on SIX, the largest Swiss IPO of the past 10 years and second largest IPO in Europe 2017
- Actelion in connection with the public tender offer by Johnson & Johnson to the shareholders of Actelion and in connection with the demerger of Idorsia from Actelion (2017)
- BioTelemetry, Inc. in connection with its competing public tender offer to the shareholders of LifeWatch AG (2017)
- Knorr-Bremse AG, the world's leading manufacturer of braking systems for rail and commercial vehicles, in the acquisition of Selectron Systems AG, Lyss (2014/2015)
- Underwriters in the CHF 2.3 billion IPO of Sunrise Communications, Switzerland's second largest telecom operator, on SIX Swiss Exchange and the financing banks in the IPO-related refinancing transactions (largest Swiss IPO since 2006 and largest IPO of telecom operator in EMEA since 2004) (2015)
- Bridgepoint in connection with the sale of Infront Sports & Media AG to Dalian Wanda Group Co. Ltd. (2015)
- NJJ Capital SAS (Xavier Niel) in the acquisition of Orange Communications SA, Switzerland's third largest telecom operator, for a total transaction value of CHF 2.8 billion (2014)
- SIX listed Leonteq in connection with its fully underwritten CHF 173 million rights offering (2014)
- OC Oerlikon Corporation AG in the CHF 1 billion acquisition of Sulzer Metco (2014)
- GlaxoSmithKline plc on its asset swap (Vaccines, Oncology) and joint venture (Consumer Healthcare) transaction with Novartis (2014)
- Cantonal Bank of Thurgau on its CHF 160 million initial public offering and listing on SIX Swiss Exchange of participation certificates (2014)

Market Perception

- "Samuel Hochstrasser is a super attorney. I've always been impressed by him."
(Chambers 2023/2024 – Healthcare & Life Sciences)